Irinotecan hydrochloride Injection 100 mg in 5 mL (10)

Land: Australië

Taal: Engels

Bron: Department of Health (Therapeutic Goods Administration)

Werkstoffen:

irinotecan hydrochloride trihydrate, Quantity: 20 mg/mL

Beschikbaar vanaf:

Pfizer (Perth) Pty Ltd

farmaceutische vorm:

Injection, concentrated

Samenstelling:

Excipient Ingredients: sorbitol; water for injections; lactic acid

Toedieningsweg:

Intravenous

Eenheden in pakket:

1 X 5 mL

Prescription-type:

(S1) This Schedule is intentionally blank

therapeutische indicaties:

Irinotecan is indicated for single-agent or combination treatment of patients with: ? Metastatic carcinoma of the colon or rectum that has recurred or progressed following 5-fluorouracil (5-FU)-based therapy ? Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. ? Previously untreated metastatic carcinoma of the colon or rectum ? Advanced cervical squamous cell carcinoma ? Irinotecan in combination with 5-FU, folinic acid (FA) and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Product samenvatting:

Visual Identification: Clear, light yellow solution, free from visible particles.; Container Type: Vial; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorisatie-status:

Listed (Export Only)

Autorisatie datum:

2019-09-03